Treatment Outcome of Bedaquiline-Based Oral Regimens for Drug-Resistant Tuberculosis in a High-Burden Setting
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
In drug-resistant tuberculosis (DR-TB) management under India’s programmatic conditions, the World Health Organization (WHO) recommends two all-oral regimens for rifampicin-resistant (RR), multidrug-resistant (MDR), and extensively drug-resistant (XDR) TB: a longer M/XDR-TB regimen (18–20 months) and a shorter bedaquiline-containing MDR/RR-TB regimen (9–11 months). Their comparative effectiveness in India remains under-evaluated.
Objective
To compare clinical and microbiological outcomes of the longer versus shorter all-oral regimens in a prospective observational cohort.
Methods
In a prospective observational cohort study f rom January to December 2022, 906 newly diagnosed MDR-TB patients at a tertiary care center in Lucknow, India, were enrolled— 691 on the longer regimen and 215 on the shorter regimen. Six-month culture conversion and final treatment outcomes were recorded. Multivariable logistic regression adjusted for age, sex, baseline smear status, and comorbidities.
Results
At 6 months, culture conversion was higher with the longer regimen (79.8% vs 67.9%; absolute difference 11.9%; p<0.001; aOR 1.51, 95% CI 1.12–2.04). Favorable treatment outcomes also favored the longer regimen (77.9% vs 69.2%; 8.7%; p=0.010; aOR 1.37, 95% CI 1.05–1.79). In subgroup analyses, differences were significant in pulmonary TB and among women; pulmonary TB independently predicted favorable outcome (aOR 1.46, 95% CI 1.01– 2.13).
Conclusions
In this single-center cohort, the longer all-oral M/XDR-TB regimen yielded superior microbiological and clinical outcomes compared to the shorter regimen. These results support regimen selection tailored by patient profile and resistance pattern, and highlight the need for robust real-world tolerability and safety monitoring.
